Medtronic is growing its heart-rhythm business through acquisitions like Affera and PulseSelect, which drive revenue and recurring procedure sales. The company gained CMS coverage for its Symplicity Spyral renal denervation, opening access to over 18 million U.S. hypertension patients. Additionally, the Hugo robotic surgery platform received initial U.S. clearance for urologic procedures, with future growth expected from more instruments and approvals. Medtronic also enhanced its spinal surgery portfolio with Stealth AXiS, integrating advanced planning and robotic assistance for complex spine operations amid favorable demographic trends.
Medtronic shares are trading at USD 102.10 on Pluang as of Nov 12, 2026 15:01 WIB, showing a modest 0.48% increase in one day. The stock maintains a strong market capitalization of $129.95 billion, reflecting sustained investor interest. All current Pluang orders are buys, indicating confidence in Medtronic's growth prospects.
